CDC and ACOG no longer recommend single dose metronidazole for the treatment of trichomoniasis in women2,3
Guidelines changed because the 2 g single-dose regimen demonstrated comparatively inferior efficacy in two separate studies—one in HIV-infected and one in HIV-uninfected women4,5:
CDC and ACOG recommend that all women presenting with vaginal discharge be screened for trichomoniasis2,3
HIV-positive patients should be screened for trich every year.2
Annual screening may also be necessary for at-risk populations, including:
  • Persons receiving care in high-prevalence settings (such as STI clinics or correctional facilities)2
  • Asymptomatic women at high risk for infection (due to behavioral risk factors such as multiple sex partners, transactional sex, drug misuse, or a history of STIs or incarceration)2
Because of the high rate of reinfection and recurrence, rescreening for trichomoniasis in women is recommended 3 months after diagnosis and treatment.2
Because of the high rate of reinfection and recurrence, rescreening for trichomoniasis in women is recommended 3 months after diagnosis and treatment.2
Help prevent reinfection by treating patients and their partner(s)2
  • 17%
    of trich patients will experience a recurrence within 3 months, most likely due to reinfection.6
  • Guidelines support treatment of partners for prevention of reinfection and recurrence.2
  • Male partners of trich patients are often asymptomatic for the infection.2


SOLOSEC is approved to treat partners of trich patients1
With SOLOSEC, you can treat partners of trichomoniasis patients with the same 2 g oral dose, at the same time.1

A partner treatment resource is available to help facilitate the conversation between patients and partners.

A partner treatment resource is available to help facilitate the conversation between patients and partners.

Options for Managing Partners
CDC recommends that partners be referred for presumptive treatment.2
Consider expedited partner therapy (EPT) where allowed by law.2
– EPT is permissible in some states.2,7
Patients should be advised to refrain from intercourse until partners are treated and symptoms resolve.2

In women, screening for trichomoniasis is recommended in all patients seeking treatment for vaginal discharge.2

CDC recommends that partners be referred for presumptive treatment.2
Consider expedited partner therapy (EPT) where allowed by law.2
– EPT is permissible in some states.2,7
Patients should be advised to refrain from intercourse until partners are treated and symptoms resolve.2

In women, screening for trichomoniasis is recommended in all patients seeking treatment for vaginal discharge.2

Take the Trich Challenge
Test your knowledge of trichomoniasis guidelines and clinical management principles based on the latest epidemiological and clinical data.
References:
1. SOLOSEC [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals, Inc; 2021. 2. Workowski KA, Bachmann LH, Chan PA, et al. CDC Sexually Transmitted Diseases Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(RR-04):1-192 3. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists, Number 215. Obstet Gynecol 2020:135(1):e1-e17. 4. Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr 2010;55:565–71. 5. Kissinger P, Muzny C, Mena L, et al. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: An open-label, randomised controlled. Lancet Infect Dis 2018;18(11):1251-1259. 6. Peterman TA, Tian LH, Metcalf CA, et al. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: a case for rescreening. Ann Intern Med 2006;145:564–72. 7. Centers for Disease Control and Prevention, Division of STD Prevention. Legal Status of Expedited Partner Therapy (EPT). Updated April 2021.